Breaking News, Collaborations & Alliances, Trials & Filings

V ClinBio, Camargo Sign Service Agreement

For V ClinBio's 2 medications, CLX-106 and CLX-103, for the treatment of relapsing-remitting multiple sclerosis (RRMS) and UC

V ClinBio Inc. has entered into a service agreement with Camargo Pharmaceutical Services. Camargo will provide end-to-end regulatory consulting and strategic development services including pre-Investigational New Drug meeting planning and preparations through New Drug Applications (NDA) submissions for V ClinBio’s two proprietary medications, CLX-106 and CLX-103, for the treatment of relapsing-remitting multiple sclerosis (RRMS) and ulcerative colitis (UC). After receiving data from initia...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters